Medpace Holdings, Inc. (MEDP) stock
MEDPNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 22, 2026Score 14/3042% above fair value
$646.87−6.22 (-0.95%)
Close on Nov 18, 2026Market cap $18.09BP/E 35.9Yield –
Medpace operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Medpace's operating income for the twelve months ending Sep 30, 2026 was $607.14M, up 19.7% year over year. For fiscal 2025 it was $534.94M, up 19.7% from the year before. Over ten years it grew 38.5% a year on average. The highest annual figure on record is $534.94M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $534.94M | +19.7% |
| FY2024 | Dec 31, 2024 | $446.87M | +32.7% |
| FY2023 | Dec 31, 2023 | $336.83M | +20.9% |
| FY2022 | Dec 31, 2022 | $278.70M | +40.3% |
| FY2021 | Dec 31, 2021 | $198.62M | +18.9% |
| FY2020 | Dec 31, 2020 | $167.04M | +31.3% |
| FY2019 | Dec 31, 2019 | $127.26M | +25.9% |
| FY2018 | Dec 31, 2018 | $101.05M | +55.8% |
| FY2017 | Dec 31, 2017 | $64.86M | +23.6% |
| FY2016 | Dec 31, 2016 | $52.49M | +155.3% |
| FY2015 | Dec 31, 2015 | $20.56M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $165.54M | +16.7% |
| Q2 FY2026 | Jun 30, 2026 | $146.82M | +16.2% |
| Q1 FY2026 | Mar 31, 2026 | $141.50M | +24.6% |
| Q4 FY2025 | Dec 31, 2025 | $153.27M | +22.2% |
| Q3 FY2025 | Sep 30, 2025 | $141.81M | +26.3% |
| Q2 FY2025 | Jun 30, 2025 | $126.34M | +20.1% |
| Q1 FY2025 | Mar 31, 2025 | $113.52M | +9.1% |
| Q4 FY2024 | Dec 31, 2024 | $125.38M | +43.6% |
| Q3 FY2024 | Sep 30, 2024 | $112.27M | +32.2% |
| Q2 FY2024 | Jun 30, 2024 | $105.15M | +34.1% |
| Q1 FY2024 | Mar 31, 2024 | $104.07M | +20.7% |
| Q4 FY2023 | Dec 31, 2023 | $87.32M | +14.2% |
| Q3 FY2023 | Sep 30, 2023 | $84.91M | +9.1% |
| Q2 FY2023 | Jun 30, 2023 | $78.39M | +30.1% |
| Q1 FY2023 | Mar 31, 2023 | $86.20M | +34.3% |
| Q4 FY2022 | Dec 31, 2022 | $76.43M | +39.3% |
| Q3 FY2022 | Sep 30, 2022 | $77.83M | +44.9% |
| Q2 FY2022 | Jun 30, 2022 | $60.24M | +41.9% |
| Q1 FY2022 | Mar 31, 2022 | $64.20M | +34.9% |
| Q4 FY2021 | Dec 31, 2021 | $54.86M | -0.2% |
| Q3 FY2021 | Sep 30, 2021 | $53.71M | +15.7% |
| Q2 FY2021 | Jun 30, 2021 | $42.45M | +40.9% |
| Q1 FY2021 | Mar 31, 2021 | $47.60M | +34.1% |
| Q4 FY2020 | Dec 31, 2020 | $54.99M | +52.2% |
| Q3 FY2020 | Sep 30, 2020 | $46.42M | +54.8% |
| Q2 FY2020 | Jun 30, 2020 | $30.13M | -14.6% |
| Q1 FY2020 | Mar 31, 2020 | $35.50M | +37.1% |
| Q4 FY2019 | Dec 31, 2019 | $36.12M | +17.8% |
| Q3 FY2019 | Sep 30, 2019 | $29.99M | +11.4% |
| Q2 FY2019 | Jun 30, 2019 | $35.26M | +51.0% |
| Q1 FY2019 | Mar 31, 2019 | $25.90M | +28.7% |
| Q4 FY2018 | Dec 31, 2018 | $30.67M | +98.7% |
| Q3 FY2018 | Sep 30, 2018 | $26.92M | +56.5% |
| Q2 FY2018 | Jun 30, 2018 | $23.35M | +43.4% |
| Q1 FY2018 | Mar 31, 2018 | $20.12M | +26.2% |
| Q4 FY2017 | Dec 31, 2017 | $15.44M | +19.8% |
| Q3 FY2017 | Sep 30, 2017 | $17.20M | – |
| Q2 FY2017 | Jun 30, 2017 | $16.28M | – |
| Q1 FY2017 | Mar 31, 2017 | $15.94M | – |
| Q4 FY2016 | Dec 31, 2016 | $12.89M | – |
See a number that looks wrong?